Bavarian Nordic A/S

Bavarian Nordic develops, manufactures, and commercializes life-saving vaccines. They offer smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola vaccines under various names. The company is also developing treatments for smallpox, RSV, and SARS-CoV-2. They have partnerships with AdaptVac, National Cancer Institute, and Public Health Service. Operations are in multiple countries across Europe, North America, Asia, Australia, and South America. The company was founded in 1992 and is headquartered in Denmark.

Overview

Sector

Biotechnology

Target Price

222.4 DKK

Current Price

169.4 DKK

Potential

31%

Strengths

With an appreciation Potential of 31.27%, based on our fundamental analysis, it suggests the stock may be undervalued.
Current Price to Earnings Ratio (13.47) is lower than the sector mean (91.15).
Price to book ratio (1.17) is lower than the sector mean (24.44).
The company has high returns. ROIC (17.07%) is higher than the sector mean (6.02%).
EV/EBITDA (7.02) is lower than the sector mean (85.60).
EV/EBIT (11.15) is lower than the sector mean.
Strong EBITDA Margin of 29.15%.

Weaknesses

The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.

Key Financial Data

Indicator	Value
PER	13.5
EV/EBITDA	7.0
Price/Free Cash Flow'	50.8
ROIC	17.1%
Net Debt/EBITDA	100.0